This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. In 2024, Otsuka announced the acquisition of US-based Jnana Therapeutics in a deal worth up to $1.1bn. Editorial content is independently produced and follows the highest standards of journalistic integrity.
Find out more Under the MoU, both companies will focus on advancing the development and mass production of lentiviral vectors, which are essential for CAR T-cell therapies used in treating leukaemia and other cancers. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
wants to ensure the ensuing the US does not lag behind other countries in drugdevelopment. The approval process for cell and gene therapy candidates is tricky, however, given their high-cost and oft-debated benefit-risk ratio. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Give your business an edge with our leading industry insights.
JCR has also developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo, to deliver biotherapeutics into the central nervous system. IZCARGO is the first drugdeveloped with this technology and approved in Japan for treating a lysosomal storage disorder.
Robert Barrie July 14, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Broader label coverages for Pfizer and Moderna’s vaccines mean they have made in-roads into GSK’s RSV dominant market share. MAXSHOT.PL via Shutterstock. Give your business an edge with our leading industry insights.
The company is confident that these concerns, which pertain to facilities and processes rather than product quality, can be promptly addressed. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Efforts are underway to work with the FDA to resolve them.
The future of DMD drugdevelopment now hinges on who steps into the role and how the FDA navigates this high-profile therapeutic area.” ” The public playout of DMD treatment developers with the FDA is not only impacting biopharma share prices but also raising concerns about the agency’s internal operations.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Give your business an edge with our leading industry insights.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Give your business an edge with our leading industry insights.
Better insights into how SDoH affects health can highlight the systemic influences that leave certain groups with worse health outcomes than others, despite similar health insurancecoverage or access. For example, it’s important to consider whether someone has insurance (public or private), a job, and what their income may be.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content